Trial Profile

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Endometrial cancer
Focus Registrational; Therapeutic Use
Acronyms LEAP-001
Sponsors Merck Sharp & Dohme Corp.

20 Feb 2025 Status changed from active, no longer recruiting to completed.
05 Sep 2024 According to an Eisai media release, data from this study will be presented in the ESMO Congress 2024 on September 14, 2024.
10 Jun 2024 Planned End Date changed from 10 Apr 2025 to 15 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com